Medicure Inc (MCUJF) stock
MCUJFOTCPharmaceutical PreparationsFiscal year ends December 31
$3.10+0.12 (+4.07%)
Close on Oct 19, 2026
Medicure r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was C$3.18M, up 3.2% from the year before. Over ten years it grew -4.2% a year on average. The highest annual figure on record is C$6.68M in fiscal 2018.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | C$3.18M | +3.2% |
| FY2024 | Dec 31, 2024 | C$3.08M | +28.1% |
| FY2023 | Dec 31, 2023 | C$2.41M | -12.6% |
| FY2022 | Dec 31, 2022 | C$2.75M | +53.3% |
| FY2021 | Dec 31, 2021 | C$1.80M | -45.6% |
| FY2020 | Dec 31, 2020 | C$3.30M | -24.1% |
| FY2019 | Dec 31, 2019 | C$4.35M | -34.9% |
| FY2018 | Dec 31, 2018 | C$6.68M | +29.8% |
| FY2017 | Dec 31, 2017 | C$5.15M | +41.8% |
| FY2016 | Dec 31, 2016 | C$3.63M | -25.4% |
| FY2015 | Dec 31, 2015 | C$4.87M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | C$570.00K | – |
| Q1 FY2024 | Mar 31, 2024 | C$676.00K | – |
See a number that looks wrong?